New combo therapy targets melanoma in the brain
NCT ID NCT05704647
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether combining two immunotherapy drugs, nivolumab and relatlimab, can help control melanoma that has spread to the brain. About 30 adults with active brain metastases will receive the drugs by IV. Researchers will monitor side effects and how well the treatment works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab and relatlimab (immunotherapy drugs given by IV)
What this could lead to
If it works, this could offer a new treatment option for melanoma that has spread to the brain, helping control the disease.
What could go wrong
This is a small, early-phase trial with only 30 people, so results may not apply to everyone. The drugs can cause immune-related side effects, and there is no guarantee they will shrink brain tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA (SKIN) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact